Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Significant Decrease in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 4,100 shares, a decline of 33.9% from the November 30th total of 6,200 shares. Based on an average daily trading volume, of 34,900 shares, the short-interest ratio is currently 0.1 days.

Bavarian Nordic A/S Price Performance

Shares of BVNRY opened at $8.98 on Friday. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of 13.01 and a beta of 1.65. Bavarian Nordic A/S has a 1 year low of $6.86 and a 1 year high of $14.60. The business’s 50 day simple moving average is $9.43 and its 200-day simple moving average is $9.99.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.